Liver Transplantation Evaluation in Decompensated Cirrhosis

Indications for Transplant Referral

Patients with cirrhosis should be referred for transplantation when they develop evidence of hepatic dysfunction or experience their first major complication, including ascites, variceal bleeding, or hepatic encephalopathy, as recommended by the American Association for the Study of Liver Diseases (AASLD) 1, 2
The presence of ascites alone carries significant mortality risk and is an indication for transplant referral independent of the MELD score, according to the AASLD guidelines 1, 2
The development of ascites as a first major complication is itself an indication for transplant referral, regardless of the MELD score, as stated by the AASLD 1, 2

The MELD score is calculated using three objective laboratory values and provides a continuous scale from 6 to 40 that predicts 3-month mortality rates, with a score of 6 associated with 90% survival and a score of 40 associated with 7% survival 1, 2
MELD-Na incorporates serum sodium and improves mortality prediction, particularly in patients with hyponatremia, as recommended by the European Association for the Study of the Liver (EASL) 3, 4
MELD 3.0 is the newest iteration, adding serum albumin and patient sex to reduce gender disparities and improve discrimination, with a C-statistic of 0.869 vs 0.862 for MELD-Na, as reported by the EASL 3, 4

MELD ≥15 is the established threshold for transplant listing because patients with MELD ≤14 have better 1-year survival without transplantation than with it, according to the United Network for Organ Sharing (UNOS) 3, 5
Patients should be referred for evaluation at lower MELD scores if they have decompensating complications, as recommended by the AASLD 1, 2

Type I hepatorenal syndrome requires expedited referral due to a median survival of less than 2 weeks without transplant, as stated by the International Liver Transplantation Society (ILTS) 1, 2
Spontaneous bacterial peritonitis is associated with less than 50% survival at 1 year after development, according to the AASL 1, 2
Certain conditions, such as hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, and refractory ascites, require standardized exception points because MELD inadequately reflects their mortality risk, as recommended by the EASL 3, 4

For patients with MELD ≥15, particularly those at MELD 23 or higher, living donor liver transplantation should be discussed as it offers survival benefit and avoids progressive decompensation while waiting, according to the EASL 5
Living donor liver transplantation allows for scheduled, elective surgery when the patient is optimized rather than emergency transplant during acute decompensation, potentially improving quality of life outcomes, as reported by the EASL 5